Frequently asked questions Microdosing GLP-1 may be considered by licensed providers for certain patients
In head-to-head clinical trial data, tirzepatide produced significantly greater average weight loss than semaglutide about 20% versus about 14% of body weight over 72 weeks
These findings need to be interpreted with caution, as conditions were not optimized to capture meal-induced changes
Lowering standards for safety and efficacy for people with obesity reinforces harmful inequities in care, Dr
For example, if you signed up on April 14th, your membership will be invoiced on the 14th of each month, and your included services will load onto your account on that day
Neurodegeneration and Cognitive Function Research: Research shows it has potential in combating neurodegeneration and cognitive decline by targeting senescent cells, a key driver of age-related diseases like Alzheimers